Assure Holdings reported Q1 2024 revenue of $9,000, down 92% from $115,000 in Q1 2023, with a net loss of $3.76 million compared to $3.14 million loss year-over-year. The decline reflects the company's strategic exit from managed service agreements. Operating expenses increased 16% to $3.73 million, primarily due to higher legal fees related to asset sales and merger activities.The company completed the sale of most clinical operations to MPOWER Health on March 26, 2024 for up to $4.5 million, including $2.3 million in cash and potential earnout payments of $2.2 million. Additionally, Assure entered into a merger agreement with Danam Health in February 2024, where former Assure shareholders will own approximately 10% of the combined company post-merger.The company faces continued Nasdaq listing compliance challenges, though received an extension until July 22, 2024 to meet requirements through the Danam merger. Working capital was negative $19 million as of March 31, 2024, with management noting substantial doubt about continuing as a going concern. The company settled a DOJ investigation for $1 million payable over 12 months.

Assure Holdings reported Q1 2024 revenue of $9,000, down 92% from $115,000 in Q1 2023, with a net loss of $3.76 million compared to $3.14 million loss year-over-year. The decline reflects the company's strategic exit from managed service agreements. Operating expenses increased 16% to $3.73 million, primarily due to higher legal fees related to asset sales and merger activities.The company completed the sale of most clinical operations to MPOWER Health on March 26, 2024 for up to $4.5 million, including $2.3 million in cash and potential earnout payments of $2.2 million. Additionally, Assure entered into a merger agreement with Danam Health in February 2024, where former Assure shareholders will own approximately 10% of the combined company post-merger.The company faces continued Nasdaq listing compliance challenges, though received an extension until July 22, 2024 to meet requirements through the Danam merger. Working capital was negative $19 million as of March 31, 2024, with management noting substantial doubt about continuing as a going concern. The company settled a DOJ investigation for $1 million payable over 12 months.